|
1
|
Sarbia M, Stahl M, Fink U, Willers R,
Seeber S and Gabbert HE: Expression of apoptosis-regulating
proteins and outcome of esophageal cancer patients treated by
combined therapy modalities. Clin Cancer Res. 4:2991–2997.
1998.PubMed/NCBI
|
|
2
|
Takeuchi H, Ozawa S, Ando N, Kitagawa Y,
Ueda M and Kitajima M: Cell-cycle regulators and the Ki-67 labeling
index can predict the response to chemoradiotherapy and the
survival of patients with locally advanced squamous cell carcinoma
of the esophagus. Ann Surg Oncol. 10:792–800. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Makino T, Yamasaki M, Miyata H, Yoshioka
S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M and Doki
Y: p53 Mutation status predicts pathological response to
chemoradiotherapy in locally advanced esophageal cancer. Ann Surg
Oncol. 17:804–811. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishida M, Morita M, Saeki H, Ohga T,
Sadanaga N, Watanabe M, Kakeji Y and Maehara Y: Expression of p53
and p21 and the clinical response for hyperthermochemoradiotherapy
in patients with squamous cell carcinoma of the esophagus.
Anticancer Res. 27:3501–3506. 2007.PubMed/NCBI
|
|
5
|
Ressiot E, Dahan L, Liprandi A, Giorgi R,
Djourno XB, Padovani L, Alibert S, Ries P, Laquière A, Laugier R,
Thomas P and Seitz JF: Predictive factors of the response to
chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol.
32:567–577. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malik SM, Nevin DT, Cohen S, Hunt JL and
Palazzo JP: Assessment of immunohistochemistry for p16INK4 and
high-risk HPV DNA by in situ hybridization in esophageal squamous
cell carcinoma. Int J Surg Pathol. 19:31–34. 2011.PubMed/NCBI
|
|
7
|
Sarbia M, Stahl M, Fink U, Heep H,
Dutkowski P, Willers R, Seeber S and Gabbert HE: Prognostic
significance of cyklin D1 in esophageal squamous cell carcinoma
patients treated with surgery alone or combined therapy modalities.
Int J Cancer. 84:86–91. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
No authors listed:. Prognostic
significance of CyclinD1 and E-Cadherin in patients with esophageal
squamous cell carcinoma: multiinstitutional retrospective analysis.
Research Committee on Malignancy of Esophageal Cancer, Japanese
Society for Esophageal Diseases. J Am Coll Surg. 192:708–718. 2001.
View Article : Google Scholar
|
|
9
|
Kuwahara A, Yamamori M, Fujita M, Okuno T,
Tamura T, Kadoyama K, Okamura N, Nakamura T and Sakaeda T: TNFRSF1B
A1466G genotype is predictive of clinical efficacy after treatment
with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy
in Japanese patients with esophageal squamous cell carcinoma. J Exp
Clin Cancer Res. 29:1002010. View Article : Google Scholar
|
|
10
|
Izzo JG, Correa AM, Wu TT, Malhotra U,
Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN,
Aggarwal BB and Ajani JA: Pretherapy nuclear factor-kappaB status,
chemoradiation resistance, and metastatic progression in esophageal
carcinoma. Mol Cancer Ther. 5:2844–2850. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pühringer-Oppermann F, Sarbia M, Ott N and
Brücher BL: The predictive value of genes of the TGF-beta1 pathway
in multi-modally treated squamous cell carcinoma of the esophagus.
Int J Colorectal Dis. 25:515–521. 2010.PubMed/NCBI
|
|
12
|
Yamashita K, Mori M, Shiraishi T, Shibuta
K and Sugimachi K: Clinical significance of matrix
metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer
Res. 6:1169–1174. 2000.PubMed/NCBI
|
|
13
|
Takatori H, Natsugoe S, Okomura H,
Matsumoto M, Ishigami S, Owaki T and Aikou T: Predictive value of
COX-2 for the effect of chemoradiotherapy on esophageal squamous
cell carcinoma. Oncol Rep. 13:697–701. 2005.PubMed/NCBI
|
|
14
|
Akutsu Y, Hanari N, Yusup G,
Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y
and Matsubara H: COX2 expression predicts resistance to
chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg
Oncol. 18:2946–2951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii
T, Kuwakado S and Katsu K: Epidermal growth factor receptor is a
possible predictor of sensitivity to chemoradiotherapy in the
primary lesion of esophageal squamous cell carcinoma. Jpn J Clin
Oncol. 37:652–657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogawa K, Chiba I, Morioka T, Shimoji H,
Tamaki W, Takamatsu R, Nishimaki T, Yoshimi N and Murayama S:
Clinical significance of HIF-1alpha expression in patients with
esophageal cancer treated with concurrent chemoradiotherapy.
Anticancer Res. 31:2351–2359. 2011.
|
|
17
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Handbook. 5th
edition. Lippincott-Raven; Philadelphia, PA: 1997
|
|
18
|
Yamashita H, Okuma K, Wakui R,
Kobayashi-Shibata S, Ohtomo K and Nakagawa K: Details of recurrence
sites after elective nodal irradiation (ENI) using 3D-conformal
radiotherapy (3D-CRT) combined with chemotherapy for thoracic
esophageal squamous cell carcinoma - a retrospective analysis.
Radiother Oncol. 98:255–260. 2011. View Article : Google Scholar
|
|
19
|
Yamashita H, Okuma K, Seto Y, Mori K,
Kobayashi S, Wakui R, Ohtomo K and Nakagawa K: A retrospective
comparison of clinical outcomes and quality of life measures
between definitive chemoradiation alone and radical surgery for
clinical stage II–III esophageal carcinoma. J Surg Oncol.
100:435–441. 2009.PubMed/NCBI
|
|
20
|
Yamashita H, Nakagawa K, Yamada K,
Kaminishi M, Mafune K and Ohtomo K: A single institutional
non-randomized retrospective comparison between definitive
chemoradiotherapy and radical surgery in 82 Japanese patients with
resectable esophageal squamous cell carcinoma. Dis Esophagus.
21:430–436. 2008. View Article : Google Scholar
|
|
21
|
Krajewska M, Krajewski S, Epstein JI,
Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC:
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1
expression in prostate cancers. Am J Pathol. 148:1567–1576.
1996.PubMed/NCBI
|
|
22
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Escárcega RO, Fuentes-Alexandro S,
García-Carrasco M, Gatica A and Zamora A: The transcription factor
nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol).
19:154–61. 2007.
|
|
25
|
Koltz BR, Hicks DG and Whitney-Miller CL:
HER2 testing in gastric and esophageal adenocarcinoma: new
diagnostic challenges arising from new therapeutic options. Biotech
Histochem. 87:40–45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akamatsu M, Matsumoto T, Oka K, Yamasaki
S, Sonoue H, Kajiyama Y, Tsurumaru M and Sasai K: c-erbB-2
oncoprotein expression related to chemoradioresistance in
esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys.
57:1323–1327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mimura K, Kono K, Hanawa M, Mitsui F,
Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER-2/neu
expression and gene amplification in patients with oesophageal
squamous cell carcinoma. Br J Cancer. 92:1253–1260. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang QM, Yuan L, Qi YJ, Ma ZY and Wang LD:
Estrogen analogues: promising target for prevention and treatment
of esophageal squamous cell carcinoma in high risk areas. Med Sci
Monit. 16:HY19–HY22. 2010.PubMed/NCBI
|
|
29
|
Lane DP: A death in the life of p53.
Nature. 362:786–787. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 Is a universal inhibitor of cyclin
kinase. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
el-Deiry WS, Harper JW, O’Connor PM,
Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill
DE and Wang Y: WAF1/CIP1 is induced in p53-mediated G1 arrest and
apoptosis. Cancer Res. 54:1169–1174. 1994.PubMed/NCBI
|
|
32
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Legan M: Cyclooxygenase-2, p53 and glucose
transporter-1 as predictors of malignancy in the development of
gallbladder carcinomas. Bosn J Basic Med Sci. 10:192–196.
2010.PubMed/NCBI
|
|
35
|
Ii M, Yamamoto H, Adachi Y, Maruyama Y and
Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in
human cancer invasion, apoptosis, growth, and angiogenesis. Exp
Biol Med (Maywood). 231:20–27. 2006.PubMed/NCBI
|
|
36
|
Smith TG, Robbins PA and Ratcliffe PJ: The
human side of hypoxia-inducible factor. Br J Haematol. 141:325–334.
2008. View Article : Google Scholar : PubMed/NCBI
|
